Loading
XTOP Biotherapeutics
XTOP Biotherapeutics is a Worcester, Massachusetts company that designs antibodies binding three targets at once to steer T cells onto cancer cells. Its lead, CB-101, is aimed at colon, pancreatic and lung cancers.
Also called: XTOP BIOTHERAPEUTICS INC.
Overview
XTOP Biotherapeutics Inc., of Worcester, Massachusetts, builds multispecific antibodies on its CrossBody platform, which it says lets it tune tumour and T-cell binding to reduce the risk of cytokine release syndrome and conceal tumour-antigen binding to limit toxicity in normal tissue. Its lead, CB-101, is described as a trispecific T-cell engager for colon, pancreatic and lung cancers; the company also announced a research collaboration with Daiichi Sankyo. In fiscal year 2026 the National Cancer Institute funded its SBIR project on CB-101, a trispecific antibody targeting ROR1, EpCAM and CD3 for colorectal cancer and other solid tumours (1R43CA310454-01A1, USD 400,000).
Headquarters
Worcester, MA, US
Scorecard
All companies#530of 1706 companies, score 8
- targets +6
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 3 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR Phase I (R43) award 1R43CA310454-01A1: Study of CB-101: A Novel First-in-Class Trispecific Antibody Targeting ROR1, EpCAM, and CD3 for the Treatment of Colorectal Cancer and Other Solid Tumors | 2026 | $400K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1PreclinicalTrispecific antibody (T-cell engager)
CB-101 is a three-armed antibody from XTOP Biotherapeutics that steers T cells to tumour cells carrying both ROR1 and EpCAM, in laboratory development for colon, pancreatic and lung cancers.
Notes
- Read on xtopbiotherapeutics.com (home and pipeline pages) and the NIH RePORTER record on 4 November 2026. The targets of CB-101 are from the award title; the website does not name them.
Connected
8Similar pages
- CompanyVitruviae
Shares Trispecific antibodies, CD3, T-cell engagers (bispecific).
- CompanyShine-On Biomedical
Shares Trispecific antibodies, CD3, T-cell engagers (bispecific), Colorectal cancer.
- CompanyExcalipoint Therapeutics
Shares Trispecific antibodies, T-cell engagers (bispecific).
- TreatmentM701
Shares EpCAM, CD3, T-cell engagers (bispecific).
- TreatmentCatumaxomab
Shares EpCAM, CD3, T-cell engagers (bispecific), Colorectal cancer.
- TreatmentTB-Bs1
Shares CD3, T-cell engagers (bispecific).
- TreatmentGlyTR1
Shares CD3, T-cell engagers (bispecific).
- TreatmentLTZ-232
Shares EpCAM, Colorectal cancer.
cancers
fronts
technologies
targets
drugs
PreclinicalTrispecific antibody (T-cell engager)
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
xtopbiotherapeutics.com · 2
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/